Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.030% | 14.662% | 21.194% | 38.468% | -0.241% | -1.985% | 36.497% |
| IQVIA Holdings Inc. | -1.940% | 11.421% | 20.580% | 25.207% | 5.593% | -0.049% | -2.393% |
| Incyte Corp. | -2.770% | 0.145% | 4.444% | 57.955% | 23.071% | 78.769% | 58.924% |
| Vertex Pharmaceuticals Inc. | -1.050% | -1.465% | -4.831% | 3.309% | 5.604% | 29.044% | 143.324% |
Comments
News
Regeneron Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Regeneron Pharmaceuticals, Inc.? Here are five stocks we like better.
- Regeneron delivered strong second-quarter growth: Revenue rose 17% year over year to $4.3 billion
Sanofi Q2 Earnings Call Highlights
Key Points
- Interested in Sanofi? Here are five stocks we like better.
- Sanofi raised its 2026 outlook after second-quarter sales rose 17.8% to €11.6 billion and business EPS increased 33.3%
2 Underrated Weight Loss Stocks to Buy and Hold
Investors interested in weight-loss stocks may naturally gravitate toward Eli Lilly and Novo Nordisk. That makes sense. They are currently the leaders in this niche. Their brands, Zepbound and
